Valsartan/2-Aminopyridine Co-Amorphous System: Preparation, Characterization, and Supramolecular Structure Simulation by Density Functional Theory Calculation

Valsartan/2-Aminopyridine Co-Amorphous System: Preparation, Characterization, and Supramolecular Structure Simulation by Density Functional Theory Calculation

The objective of this work was to improve the solubility and discover a stable co-amorphous form of valsartan (VAL), a BCS class-II drug, by utilizing small molecule 2-Aminopyridine (2-AP) in varying molar ratios (2:1, 1:1, and 1:2), employing a solvent evaporation technique. Additionally, by way of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Linjie Wang, Chunan Du, Yang Yang, Pengtu Zhang, Shiling Yuan
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Molecules
Subjects:	co-amorphous valsartan DFT supermolecule intermolecular connectivity
Online Access:	https://www.mdpi.com/1420-3049/29/22/5467
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan/Amlodipine (80/5 Mg) in Healthy Chinese Subjects
by: Tian M, et al.
Published: (2025-01-01)

Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures
by: Stolarczyk Mariusz, et al.
Published: (2017-12-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
by: Musko Monika, et al.
Published: (2014-12-01)

Efficacy of valsartan combined with fermented cordyceps sinensis-4 in the treatment of diabetic nephropathy
by: Yiquan Wang, et al.
Published: (2024-12-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Drug–Phospholipid Co-Amorphous Formulations: The Role of Preparation Methods and Phospholipid Selection
by: Keyoomars Khorami, et al.
Published: (2024-12-01)

Integrating Metabolomics, Histopathology, and Cardiac Marker Analysis to Assess Valsartan’s Efficacy in Mitigating Dasatinib-Induced Cardiac Toxicity in Sprague-Dawley Rats
by: Alhazzani K, et al.
Published: (2024-12-01)

Sex differences and clinical outcomes, including ventricular tachyarrhythmias, of patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
by: Mohammad Abumayyaleh, et al.
Published: (2024-12-01)

An Overlooked Supramolecular Synthon in Multicomponent Trimethylglycine Crystals: Moderate Hydrogen Bonding Between Carboxylate and H-N Groups of Guanidine Species
by: Andrei V. Churakov, et al.
Published: (2024-11-01)

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01)

Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study
by: Yu Yan, et al.
Published: (2025-01-01)

Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01)

Tribocorrosion behavior of Al-based amorphous coatings prepared by different spraying methods
by: Jiachi Yuan, et al.
Published: (2025-03-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

A Discussion on the Phonon Density of States of Amorphous Germanium for the Infrared Range
by: M. A. Grado-Caffaro, et al.
Published: (1998-01-01)

A Small Cluster Approach for the Electronic Density of States in Amorphous Germanium
by: M. A. Grado-Caffaro, et al.
Published: (1998-01-01)

Determination of Sacubitril and Valsartan Binary Mixture using Different Eco-friendly Spectrophotometric approaches with or without Regression Equations; greenness and whiteness assessments
by: Ragaa Magdy, et al.
Published: (2023-06-01)

A review of the preparation and prospects of amorphous alloys by mechanical alloying
by: Xian-jie Yuan, et al.
Published: (2024-11-01)

Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and solution stability evaluation
by: Ali Ahmed Mahmoud Abdelhaleem, et al.
Published: (2015-06-01)

A clinical randomized trial: Effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in acute myocardial infarction patients
by: Zhengfeng Liu, et al.
Published: (2024-12-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis
by: Xinyue Yang, et al.
Published: (2024-12-01)

Efficacy and safety of sacubitril/valsartan on postoperative atrial fibrillation in adult patients undergoing cardiac surgery: a real-world observational study
by: Xiaodong Chen, et al.
Published: (2024-11-01)

Development of silver-doped carbon dots sensor derived from lignin for dual-mode fluorometric and spectrophotometric determination of valsartan in a bulk powder and a commercial product
by: Fatemah Aldakhil, et al.
Published: (2024-12-01)

Efficacy and safety of sacubitril/valsartan in the treatment of atrial fibrillation after ablation: a Meta-analysis
by: BI Longfei, et al.
Published: (2024-08-01)

An Analytical Study on the Local Electronic Density of States of the Valence Bands in Amorphous Silicon Carbide
by: M. A. Grado-Caffaro, et al.
Published: (1998-01-01)

Performance of amorphous TiO2@Ag/AgBr composite photocatalyst prepared by spray pyrolysis
by: WU Rui, et al.
Published: (2023-06-01)

Enhancing water solubility of phytosterols through Co-amorphization with food-grade coformers
by: Yuxin Li, et al.
Published: (2025-01-01)

Excellent Magnetocaloric Properties near 285 K of Amorphous Fe<sub>88</sub>Pr<sub>6</sub>Ce<sub>4</sub>B<sub>2</sub> Ribbon
by: Xiangjie Liu, et al.
Published: (2024-10-01)

A Brief Study to Clarify Some Aspects Related to Vibrational Density of States for the Far Infrared Range in Amorphous Semiconductors
by: M. A. Grado-Caffaro, et al.
Published: (1998-01-01)

FeNi-Based Aerogels Containing FeNi<sub>3</sub> Nanoclusters Embedded with a Crystalline–Amorphous Heterojunction as High-Efficiency Oxygen Evolution Catalysts
by: Tao Li, et al.
Published: (2024-11-01)

Assessment of Left Ventricular Reverse Remodeling by Echocardiography After 90 Days of Sacubitril/Valsartan Therapy in Patients of Heart Failure with Reduced Ejection Fraction
by: Akshay Pawar, et al.
Published: (2024-12-01)

Synthesis of polyacrylic acid-citrate-amorphous calcium phosphate and its effect on dentin remineralization
by: CHEN Yinying, CHEN Chen
Published: (2024-11-01)

Coarse-graining amorphous plasticity: impact of rejuvenation and disorder
by: Tyukodi, Botond, et al.
Published: (2023-06-01)

Advancements in Amorphous Oxides For Electrocatalytic Carbon Dioxide Reduction
by: Youcai Meng, et al.
Published: (2024-12-01)

Preparation and properties of Fe−Si−B−Cr−C amorphous alloy powders by air-water combination atomization with different particle sizes
by: LÜ Shiya, et al.
Published: (2024-12-01)